Title |
Miltefosine Suppresses Inflammation in a Mouse Model of Inflammatory Bowel Disease
|
---|---|
Published in |
Inflammatory Bowel Diseases, June 2013
|
DOI | 10.1097/mib.0b013e3182917a2b |
Pubmed ID | |
Authors |
Auke P. Verhaar, Manon E. Wildenberg, Anje A. te Velde, Sybren L. Meijer, Anne Christine W. Vos, Marjolijn Duijvestein, Maikel P. Peppelenbosch, Daniel W. Hommes, Gijs R. van den Brink |
Abstract |
The repertoire of immunomodulators that can be used for the treatment of inflammatory bowel disease is limited. The use of these drugs is further restricted by the occurrence of side effects in a proportion of patients. Miltefosine (hexadecylphosphocholine) is a lipid drug developed in the 1980s for the treatment of cancer but is nowadays best known for its application in the oral treatment of leishmaniasis. Although the exact mechanism of action of miltefosine has yet to be elucidated, the drug has previously been shown to inhibit phospholipases and protein kinase C, both key components of proproliferative signal transduction in T cells. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 29% |
Student > Master | 5 | 29% |
Student > Ph. D. Student | 3 | 18% |
Professor | 2 | 12% |
Other | 1 | 6% |
Other | 0 | 0% |
Unknown | 1 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 5 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 18% |
Medicine and Dentistry | 2 | 12% |
Business, Management and Accounting | 1 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 6% |
Other | 2 | 12% |
Unknown | 3 | 18% |